Literature DB >> 31545985

ER-mediated anti-tumor effects of shikonin on breast cancer.

Yang Yang1, Wenya Gao1, Shiying Tao2, Yanxia Wang3, Jianzhao Niu1, Piwen Zhao4, Chenchen Rao1, Lei Yang5.   

Abstract

Estrogen receptor (ER) is expressed in most Breast cancer (BC) patients. G protein-coupled estrogen receptor (GPER), which is a membrane-bound estrogen receptor, is associated with the tumor development and progression in BC. Shikonin (SK) is a natural compound that is known to have anti-tumor effects. This study aims to assess the effects of shikonin on the cell proliferation, cell cycle and cell apoptosis of BC and whether the effects are related to ER/GPER signaling pathway. The results demonstrated that shikonin inhibited the cellular proliferation of MCF-7 BC cells via G0/G1 arrest and apoptosis in concentration-dependent manner. The anti-proliferative effect of SK on SK-BR-3 BC cells was associated with apoptosis. Both ERα and GPER were expressed in MCF-7 cells, while ERα were negative and GPER were positive in SK-BR-3 cells. Furthermore, shikonin downregulated the expression of ERα and GPER, and this effect was not affected by the estrogen environment. In addition, shikonin downregulated the EGFR and p-ERK expression in MCF-7 and SK-BR-3, which was also not affected by the estrogen environment. EGFR and p-ERK were still suppressed by co-treatment with the selective GPER against G1 or antagonist G15. In conclusion, these results suggest that shikonin shows anti-tumor effects on MCF-7 and SK-BR-3 cells. The effects seem to be associated with EGFR/p-ERK downregulation via ERα and GPER inhibition.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Breast cancer; Estrogen receptor; G protein-coupled estrogen receptor; Shikonin

Mesh:

Substances:

Year:  2019        PMID: 31545985     DOI: 10.1016/j.ejphar.2019.172667

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  6 in total

Review 1.  Recent Advances and the Mechanism of Astaxanthin in Ophthalmological Diseases.

Authors:  Ming Yang; Yanling Wang
Journal:  J Ophthalmol       Date:  2022-05-20       Impact factor: 1.974

2.  Shikonin promotes ubiquitination and degradation of cIAP1/2-mediated apoptosis and necrosis in triple negative breast cancer cells.

Authors:  Anqi Wang; Jiayu Liu; Yuhan Yang; Zhejie Chen; Caifang Gao; Zhanguo Wang; Chaomei Fu; Liang Zou; Shengpeng Wang
Journal:  Chin Med       Date:  2021-02-01       Impact factor: 5.455

3.  Shikonin Inhibits Cell Growth of Sunitinib-Resistant Renal Cell Carcinoma by Activating the Necrosome Complex and Inhibiting the AKT/mTOR Signaling Pathway.

Authors:  Sascha D Markowitsch; Olesya Vakhrusheva; Patricia Schupp; Yasminn Akele; Jovana Kitanovic; Kimberly S Slade; Thomas Efferth; Anita Thomas; Igor Tsaur; René Mager; Axel Haferkamp; Eva Juengel
Journal:  Cancers (Basel)       Date:  2022-02-22       Impact factor: 6.639

Review 4.  Review of Shikonin and Derivatives: Isolation, Chemistry, Biosynthesis, Pharmacology and Toxicology.

Authors:  Snehlata Yadav; Ajay Sharma; Gulzar Ahmad Nayik; Raymond Cooper; Garima Bhardwaj; Harvinder Singh Sohal; Vishal Mutreja; Ramandeep Kaur; Franklin Ore Areche; Mohannad AlOudat; Ayaz Mukarram Shaikh; Béla Kovács; Abdelhakam Esmaeil Mohamed Ahmed
Journal:  Front Pharmacol       Date:  2022-07-01       Impact factor: 5.988

Review 5.  Herbal Ingredients in the Prevention of Breast Cancer: Comprehensive Review of Potential Molecular Targets and Role of Natural Products.

Authors:  Esra Küpeli Akkol; Hilal Bardakci; Timur Hakan Barak; Michael Aschner; Gökçe Şeker Karatoprak; Haroon Khan; Yaseen Hussain
Journal:  Oxid Med Cell Longev       Date:  2022-08-16       Impact factor: 7.310

6.  Shikonin Mediates Apoptosis through G Protein-Coupled Estrogen Receptor of Ovarian Cancer Cells.

Authors:  Xinyue Liu; Yao Yang; Xuefei Tang; Li Guo; Xinhui Tang; Ting Zhu; Tiannan Zhao; Weina Zhang; Ping Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2022-10-05       Impact factor: 2.650

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.